Andere Sprachen Seres Therapeutics, Inc.

Aktien

A14VXX

US81750R1023

MCRB

Realtime-Estimate Cboe BZX Andere Börsenplätze 17:00:04 23.05.2024			% 5 Tage	% 1. Jan.
0,928 ^USD	-0,99 %		+0,06 %	-33,93 %

09.05.	SERES THERAPEUTICS, INC. : Oppenheimer behält seine Kaufempfehlung bei	ZM
09.05.	SERES THERAPEUTICS, INC. : Chardan Research bekräftigt seine neutrale Bewertung	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Seres Therapeutics: Q1 Earnings Snapshot	08.05.
Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates	08.05.
Seres Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08.05.
Seres Therapeutics : Accelaration/Increase of Financial Obligation - Form 8-K	07.05.
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	06.05.
Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024	06.05.
Foreign automakers eager for Chinese partners at Beijing auto show	26.04.
Battle for 'tech luxury' in China as EVs get smarter - and cheaper	25.04.
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences	09.04.
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT	09.04.
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT	09.04.
Declaration of Voting Results by Seres Therapeutics	08.04.
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	28.03.
SERES THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)	20.03.
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	19.03.
Seres Therapeutics Files a Definitive Proxy Statement with Securities and Exchange Commission	05.03.
Seres Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	05.03.
Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates	05.03.
North American Morning Briefing : S&P 500 Futures -2-	05.03.
Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024	28.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Seres Therapeutics, Inc.

Aktien

A14VXX

US81750R1023

MCRB

Andere Sprachen

Filter